Quintiles Transnational Holdings Inc (Q) was Downgraded by Wells Fargo to ” Market Perform”. Earlier the firm had a rating of “Outperform ” on the company shares. Wells Fargo advised their investors in a research report released on May 12, 2016.
Many Wall Street Analysts have commented on Quintiles Transnational Holdings Inc. Shares were Downgraded by Robert W. Baird on May 4, 2016 to ” Neutral” and Lowered the Price Target to $ 74 from a previous price target of $76 .Quintiles Transnational Holdings Inc was Downgraded by Citigroup to ” Neutral” on May 4, 2016. Quintiles Transnational Holdings Inc was Downgraded by Sun Trust Rbsn Humphrey to ” Neutral” on Mar 28, 2016.
On the company’s financial health, Quintiles Transnational Holdings Inc reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.86. The company had revenue of $1108.00 million for the quarter, compared to analysts expectations of $1118.63 million. The company’s revenue was up 7.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.72 EPS.
Quintiles Transnational Holdings Inc opened for trading at $67.64 and hit $68 on the upside on Tuesday, eventually ending the session at $67.65, with a gain of 0.92% or 0.62 points. The heightened volatility saw the trading volume jump to 10,50,457 shares. Company has a market cap of $8,096 M.
In a different news, on Apr 14, 2016, Kevin K Gordon (EVP and COO) sold 24,000 shares at $69.90 per share price. According to the SEC, on Sep 3, 2015, Charles Edward Williams (Sr VP and Controller) sold 5,000 shares at $72.43 per share price. On Mar 26, 2015, Michael J Evanisko (director) sold 2,500 shares at $67.10 per share price, according to the Form-4 filing with the securities and exchange commission.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services including commercial services such as contract pharmaceutical sales forces and healthcare business services such as phase research market access and consulting and health information analytics and technology consulting.